Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 55

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 55
---
 executed on our behalf by CROs based on three clinical studies. Therefore, we cannot guarantee that our employees will manage such studies effectively in the future. We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful, we may not be able to complete the development of these product candidates. Collaborations involving our product candidates pose the following risks to us:

| ● | collaborators                                                                                                      
 have significant discretion in determining the efforts and resources that they will apply to these collaborations; |

| ● | collaborators                                                                                                                                     
 may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization 
 programs based on clinical trial results, changes in the collaborator’s strategic focus or available funding, or external factors                 
 such as an acquisition that diverts resources or creates competing priorities;                                                                    |

| ● | collaborators                                                                                                                               
 may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, 
 repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;                             |

| ● | collaborators                                                                                                                            
 could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates     
 if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms 
 that are more economically attractive than ours;                                                                                         |

| ● | collaborators                                                                                                                          
 may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite 
 litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;                       |

30

| ● | collaborators                                                                                                                              
 may not comply with regulatory requirements and as a result their operations may be disrupted or ended until they resolve their regulatory 
 issues with government officials;                                                                                                          |

| ● | disputes                                                                                                                             
 may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization 
 of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;        |

| ● | collaborations                                                                                                                       
 may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization 
 of the applicable product candidates;                                                                                                |

| ● | collaborators                                                                                                                             
 may elect to take over manufacturing rather than retain us as manufacturers and may encounter problems in starting up or gaining approval 
 for their manufacturing facility and so be